EPIGENETIC THERAPY FOR FRIEDREICH’S ATAXIA: A PHASE 1, FIRST IN MAN, ASCENDING DOSE CROSSOVER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RG2833 (A HISTONE DEACETYLASE INHIBITOR) IN ADULTS WITH FRIEDREICH’S ATAXIA(2018 Mar 12).
EPIGENETIC THERAPY FOR FRIEDREICH’S ATAXIA: A PHASE 1, FIRST IN MAN, ASCENDING DOSE CROSSOVER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RG2833 (A HISTONE DEACETYLASE INHIBITOR) IN ADULTS WITH FRIEDREICH’S ATAXIA
DE MERCANTI, STEFANIA FEDERICA
2018-03-12
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Stefania Federica De Mercanti - Tesi di dottorato.pdf
Accesso aperto
Descrizione: Tesi
Dimensione
11.32 MB
Formato
Adobe PDF
|
11.32 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
